Annual Cash & Cash Equivalents
$251.10 M
-$11.80 M-4.49%
31 December 2023
Summary:
Neurocrine Biosciences annual cash & cash equivalents is currently $251.10 million, with the most recent change of -$11.80 million (-4.49%) on 31 December 2023. During the last 3 years, it has risen by +$64.00 million (+34.21%). NBIX annual cash & cash equivalents is now -26.32% below its all-time high of $340.80 million, reached on 31 December 2021.NBIX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$349.10 M
+$209.40 M+149.89%
30 September 2024
Summary:
Neurocrine Biosciences quarterly cash and cash equivalents is currently $349.10 million, with the most recent change of +$209.40 million (+149.89%) on 30 September 2024. Over the past year, it has increased by +$55.40 million (+18.86%). NBIX quarterly cash and cash equivalents is now -17.92% below its all-time high of $425.30 million, reached on 30 September 2020.NBIX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -4.5% | +18.9% |
| 3 y3 years | +34.2% | +12.2% |
| 5 y5 years | +77.2% | +109.5% |
NBIX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -26.3% | +34.2% | -11.9% | +236.3% |
| 5 y | 5 years | -26.3% | +123.6% | -17.9% | +236.3% |
| alltime | all time | -26.3% | +2122.1% | -17.9% | >+9999.0% |
Neurocrine Biosciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $349.10 M(+149.9%) |
| June 2024 | - | $139.70 M(-64.7%) |
| Mar 2024 | - | $396.30 M(+57.8%) |
| Dec 2023 | $251.10 M(-4.5%) | $251.10 M(-14.5%) |
| Sept 2023 | - | $293.70 M(+83.3%) |
| June 2023 | - | $160.20 M(+54.3%) |
| Mar 2023 | - | $103.80 M(-60.5%) |
| Dec 2022 | $262.90 M(-22.9%) | $262.90 M(+23.9%) |
| Sept 2022 | - | $212.20 M(+29.9%) |
| June 2022 | - | $163.30 M(-39.6%) |
| Mar 2022 | - | $270.20 M(-20.7%) |
| Dec 2021 | $340.80 M(+82.1%) | $340.80 M(+9.5%) |
| Sept 2021 | - | $311.10 M(-15.5%) |
| June 2021 | - | $368.00 M(+4.4%) |
| Mar 2021 | - | $352.60 M(+88.5%) |
| Dec 2020 | $187.10 M(+66.6%) | $187.10 M(-56.0%) |
| Sept 2020 | - | $425.30 M(+2.5%) |
| June 2020 | - | $415.10 M(+122.0%) |
| Mar 2020 | - | $187.00 M(+66.5%) |
| Dec 2019 | $112.30 M(-20.8%) | $112.30 M(-32.6%) |
| Sept 2019 | - | $166.64 M(+18.2%) |
| June 2019 | - | $140.99 M(+93.7%) |
| Mar 2019 | - | $72.78 M(-48.6%) |
| Dec 2018 | $141.71 M(-44.4%) | $141.71 M(-27.6%) |
| Sept 2018 | - | $195.73 M(+17.6%) |
| June 2018 | - | $166.42 M(-5.1%) |
| Mar 2018 | - | $175.31 M(-31.2%) |
| Dec 2017 | $254.71 M(+205.9%) | $254.71 M(-4.9%) |
| Sept 2017 | - | $267.82 M(-13.5%) |
| June 2017 | - | $309.50 M(+382.9%) |
| Mar 2017 | - | $64.09 M(-23.0%) |
| Dec 2016 | $83.27 M(+12.2%) | $83.27 M(-16.5%) |
| Sept 2016 | - | $99.76 M(+15.7%) |
| June 2016 | - | $86.25 M(-25.2%) |
| Mar 2016 | - | $115.30 M(+55.4%) |
| Dec 2015 | $74.19 M(+139.2%) | $74.19 M(+11.8%) |
| Sept 2015 | - | $66.38 M(-49.7%) |
| June 2015 | - | $132.07 M(-22.4%) |
| Mar 2015 | - | $170.26 M(+449.0%) |
| Dec 2014 | $31.01 M(-30.8%) | $31.01 M(+6.8%) |
| Sept 2014 | - | $29.05 M(-22.4%) |
| June 2014 | - | $37.45 M(-64.5%) |
| Mar 2014 | - | $105.53 M(+135.6%) |
| Dec 2013 | $44.79 M(-29.7%) | $44.79 M(+28.4%) |
| Sept 2013 | - | $34.89 M(-21.3%) |
| June 2013 | - | $44.31 M(+40.4%) |
| Mar 2013 | - | $31.55 M(-50.5%) |
| Dec 2012 | $63.75 M(+27.2%) | $63.75 M(+43.3%) |
| Sept 2012 | - | $44.49 M(+5.9%) |
| June 2012 | - | $42.02 M(-45.4%) |
| Mar 2012 | - | $76.94 M(+53.6%) |
| Dec 2011 | $50.11 M(-7.3%) | $50.11 M(+26.8%) |
| Sept 2011 | - | $39.52 M(+109.8%) |
| June 2011 | - | $18.84 M(-22.8%) |
| Mar 2011 | - | $24.39 M(-54.9%) |
| Dec 2010 | $54.05 M | $54.05 M(-30.1%) |
| Sept 2010 | - | $77.33 M(-18.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2010 | - | $95.12 M(+82.1%) |
| Mar 2010 | - | $52.22 M(+39.9%) |
| Dec 2009 | $37.33 M(-45.5%) | $37.33 M(+5.7%) |
| Sept 2009 | - | $35.32 M(-8.5%) |
| June 2009 | - | $38.62 M(-25.3%) |
| Mar 2009 | - | $51.66 M(-24.5%) |
| Dec 2008 | $68.47 M(-31.3%) | $68.47 M(-14.5%) |
| Sept 2008 | - | $80.13 M(-12.8%) |
| June 2008 | - | $91.92 M(-14.6%) |
| Mar 2008 | - | $107.64 M(+8.0%) |
| Dec 2007 | $99.66 M(+23.1%) | $99.66 M(+97.9%) |
| Sept 2007 | - | $50.35 M(-2.2%) |
| June 2007 | - | $51.48 M(-34.4%) |
| Mar 2007 | - | $78.46 M(-3.1%) |
| Dec 2006 | $80.98 M(+62.1%) | $80.98 M(+6.9%) |
| Sept 2006 | - | $75.76 M(-12.1%) |
| June 2006 | - | $86.17 M(-15.1%) |
| Mar 2006 | - | $101.49 M(+103.2%) |
| Dec 2005 | $49.95 M(-18.2%) | $49.95 M(-33.7%) |
| Sept 2005 | - | $75.38 M(+55.4%) |
| June 2005 | - | $48.50 M(+8.8%) |
| Mar 2005 | - | $44.57 M(-27.0%) |
| Dec 2004 | $61.03 M(-42.3%) | $61.03 M(-27.9%) |
| Sept 2004 | - | $84.69 M(+272.5%) |
| June 2004 | - | $22.73 M(-40.2%) |
| Mar 2004 | - | $38.01 M(-64.1%) |
| Dec 2003 | $105.85 M(+138.9%) | $105.85 M(-14.5%) |
| Sept 2003 | - | $123.82 M(+254.8%) |
| June 2003 | - | $34.90 M(-49.0%) |
| Mar 2003 | - | $68.41 M(+54.4%) |
| Dec 2002 | $44.31 M(-73.0%) | $44.31 M(-21.7%) |
| Sept 2002 | - | $56.63 M(+18.3%) |
| June 2002 | - | $47.86 M(-6.7%) |
| Mar 2002 | - | $51.31 M(-68.7%) |
| Dec 2001 | $163.89 M(+677.5%) | $163.89 M(+1271.9%) |
| Sept 2001 | - | $11.95 M(-53.0%) |
| June 2001 | - | $25.43 M(-6.9%) |
| Mar 2001 | - | $27.32 M(+29.6%) |
| Dec 2000 | $21.08 M(-1.0%) | $21.08 M(+88.8%) |
| Sept 2000 | - | $11.16 M(+351.6%) |
| June 2000 | - | $2.47 M(-79.4%) |
| Mar 2000 | - | $11.99 M(-43.7%) |
| Dec 1999 | $21.30 M(+82.1%) | $21.30 M(+180.3%) |
| Sept 1999 | - | $7.60 M(-36.1%) |
| June 1999 | - | $11.90 M(+91.9%) |
| Mar 1999 | - | $6.20 M(-47.0%) |
| Dec 1998 | $11.70 M(-25.9%) | $11.70 M(-37.1%) |
| Sept 1998 | - | $18.60 M(+75.5%) |
| June 1998 | - | $10.60 M(-24.8%) |
| Mar 1998 | - | $14.10 M(-10.8%) |
| Dec 1997 | $15.80 M(+39.8%) | $15.80 M(+4.6%) |
| Sept 1997 | - | $15.10 M(-34.1%) |
| June 1997 | - | $22.90 M(+218.1%) |
| Mar 1997 | - | $7.20 M(-36.3%) |
| Dec 1996 | $11.30 M | $11.30 M(+56.9%) |
| Sept 1996 | - | $7.20 M(-66.8%) |
| June 1996 | - | $21.70 M |
FAQ
- What is Neurocrine Biosciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual cash & cash equivalents year-on-year change?
- What is Neurocrine Biosciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly cash and cash equivalents year-on-year change?
What is Neurocrine Biosciences annual cash & cash equivalents?
The current annual cash & cash equivalents of NBIX is $251.10 M
What is the all time high annual cash & cash equivalents for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual cash & cash equivalents is $340.80 M
What is Neurocrine Biosciences annual cash & cash equivalents year-on-year change?
Over the past year, NBIX annual cash & cash equivalents has changed by -$11.80 M (-4.49%)
What is Neurocrine Biosciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NBIX is $349.10 M
What is the all time high quarterly cash and cash equivalents for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly cash and cash equivalents is $425.30 M
What is Neurocrine Biosciences quarterly cash and cash equivalents year-on-year change?
Over the past year, NBIX quarterly cash and cash equivalents has changed by +$55.40 M (+18.86%)